About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
SMART QUOTES
Smart
Quotes
Glaxosmithkline Pharmaceuticals Ltd.
Industry :
Pharmaceuticals & Drugs
BSE Code
500660
ISIN Demat
INE159A01016
Book Value
98.85
NSE Code
GLAXO
Dividend Yield %
1.40
Market Cap
387008.08
P/E
57.86
EPS
39.49
Face Value
10
BSE
NSE
20-Dec-2024
BSE
NSE
NSE F & O
20-Dec-2024
BSE
NSE
NSE F & O
Last Price
2284.50
Net Change
-40.75
% Change
-1.75%
Prev.Close
2325.25
Open
2342.85
High
2342.85
Low
2266.70
Volume
2104
Last Price
2275.95
Net Change
-50.35
% Change
-2.16%
Prev.Close
2326.30
Open
2325.00
High
2326.30
Low
2264.00
Volume
85491
Value
4841776
Best Buy
0.00
Best Sell
0.00
Best Quantity
0
Sell Quantity
0
Today's Range
2342.85
52-Week High
3087.95
52-Week Low
1668.20
Value
196056105.1
Best Buy
0.00
Best Sell
2275.95
Best Quantity
0
Sell Quantity
391
Today's Range
2326.30
52-Week High
3088.00
52-Week Low
1667.85
Open Price
High Price
Low Price
Last Price
Prev Close
Change
% Change
Average Price
Underlying Value
Number of contracts traded
Turnover in Rs. Lakhs
Open Interest
Change in O I
% Change in O I
%
Today
|
1W
|
1M
|
1Y
You need to upgrade your Flash Player
Best Bid
Best Offer
Quantity
0
Price
0.00
Quantity
0
Price
0.00
Best Bid
Best Offer
Quantity
0
Price
0.00
Quantity
391
Price
2275.95
Best Bid
Best Offer
Quantity
Price
Quantity
Price
Holding Details
More
Latest Corporate Events
Bonus
1 : 1
11-Sep-18
Book Closure
15-Jul-19
22-Jul-19
Dividend
120 %
07-Nov-24
Company News
27-11-2024
Glaxosmithkline Pharmaceu...
01-10-2024
Glaxosmithkline Pharmaceu...
24-09-2024
GlaxoSmithKline Pharmaceu...
26-08-2024
GlaxoSmithKline Pharmace...
14-08-2024
GlaxoSmithKline Pharmaceu...
13-08-2024
GlaxoSmithKline Pharmaceu...
08-08-2024
Glaxosmithkline Pharmaceu...
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.